New Blood: Former Novartis Exec Transitions to Rubius Therapeutics
New Red-Blood-Cell-Derived Therapies Are Poised to Launch Rubius into the Spotlight.
Improving Human Health: The Promise of Epigenetics
A New Perspective for Genomic Research from Prof. Shankar Balsubramanian
Translating Innovation into Therapies
Antimicrobial Resistance and Drug Commercialization Were Key Topics at the Recent ON Helix Conference in Cambridge, U.K.
Literature Review: Dielectrophoresis to the Fore
Old Methodology Resurrected to Allow Inexpensive Label-Free Separation of Cell Populations
For full access to this article login to GEN Select now.
Getting a Handle on Nanobiotech Products
Regulators and Companies Are Laying the Groundwork for a Predicted Bright Future
- As the regulatory pathway to approval for biotech products becomes more arduous, lengthy, and expensive, biofirms are fighting to keep pace with a rapidly changing regulatory landscape. They also are trying to find out how the FDA is going to look at nanotechnology product development. A number of biotech ...
Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.
Get GEN Select Access Now
- Do not put any letters or characters here if you are not a spy program.